AI English summary of an SEC filing — figures as filed
Edwards Lifesciences EWThe company said net sales for Q1 2025 (ended March 31) were $1,412.7 million, up 6.2% from $1,329.9 million a year earlier, and rose 7.9% on an adjusted basis.
Key points
AI summaryThe company said net sales for Q1 2025 (ended March 31) were $1,412.7 million, up 6.2% from $1,329.9 million a year earlier, and rose 7.9% on an adjusted basis.
Edwards said TAVR sales for Q1 were $1.05 billion, up 3.8% from a year earlier (5.4% on a constant currency basis), and TMTT sales were $115 million, up 58%.
The company reported that its operating profit margin from continuing operations for Q1 was 27.9% (29.1% adjusted), diluted earnings per share were $0.62 ($0.64 adjusted), and its gross profit margin was 78.7%.
The company said it expects 2025 full-year sales of $5.7 billion to $6.1 billion and adjusted EPS of $2.40 to $2.50, and that it raised its TMTT sales guidance range to $530 million to $550 million from $500 million to $530 million.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Net Sales and Adjusted Growth for Q1
The company said net sales for Q1 2025 (ended March 31) were $1,412.7 million, up 6.2% from $1,329.9 million a year earlier, and rose 7.9% on an adjusted basis.
Source · Based on the filing body and exhibits
TAVR and TMTT Sales Growth in Q1
Edwards said TAVR sales for Q1 were $1.05 billion, up 3.8% from a year earlier (5.4% on a constant currency basis), and TMTT sales were $115 million, up 58%.
Source · Based on the filing body and exhibits
Operating Margin and EPS for Q1
The company reported that its operating profit margin from continuing operations for Q1 was 27.9% (29.1% adjusted), diluted earnings per share were $0.62 ($0.64 adjusted), and its gross profit margin was 78.7%.
Source · Based on the filing body and exhibits
Full-Year 2025 and Q2 Outlook
The company said it expects 2025 full-year sales of $5.7 billion to $6.1 billion and adjusted EPS of $2.40 to $2.50, and that it raised its TMTT sales guidance range to $530 million to $550 million from $500 million to $530 million.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…